Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
Cantor pharma/biotech analysts to hold analyst/industry conference call » 10:25
04/06/20
04/06
10:25
04/06/20
10:25
PFE

Pfizer

$34.48 /

+0.85 (+2.53%)

, LLY

Eli Lilly

$141.85 /

+2.34 (+1.68%)

, MRK

Merck

$79.52 /

+3.26 (+4.27%)

, MRTX

Mirati Therapeutics

$81.81 /

+8.3 (+11.29%)

, AMGN

Amgen

$209.13 /

+3.73 (+1.82%)

, JNJ

Johnson & Johnson

$136.45 /

+2.32 (+1.73%)

, PHGE

BiomX

$6.17 /

+ (+0.00%)

Cantor Fitzgerald…

Cantor Fitzgerald Pharmaceuticals Analyst Chen & Kim, Biotech Analysts Young, Kumar & Kluska, along with Dr. Robert Fine from New York-Presbyterian/Columbia University Medical Center review current treatment paradigm for advanced and metastatic colorectal cancer (CRC) and discuss new treatments for CRC on an Analyst/Industry conference call to be held on April 6 at 11 am.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Options
Unusual call flow in option market yesterday » 07:35
04/06/20
04/06
07:35
04/06/20
07:35
PFE

Pfizer

$33.63 /

+0.78 (+2.37%)

Notable call activity was…

Notable call activity was cited Friday in Pfizer (PFE).

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
Cantor pharma/biotech analysts to hold analyst/industry conference call » 04:55
04/06/20
04/06
04:55
04/06/20
04:55
PFE

Pfizer

$33.63 /

+0.78 (+2.37%)

, LLY

Eli Lilly

$139.51 /

-2.64 (-1.86%)

, MRK

Merck

$76.26 /

-0.65 (-0.85%)

, MRTX

Mirati Therapeutics

$73.51 /

-1.86 (-2.47%)

, AMGN

Amgen

$205.40 /

-3.64 (-1.74%)

, JNJ

Johnson & Johnson

$134.13 /

+1.05 (+0.79%)

, PHGE

BiomX

$6.17 /

-0.835 (-11.93%)

Cantor Fitzgerald…

Cantor Fitzgerald Pharmaceuticals Analyst Chen & Kim, Biotech Analysts Young, Kumar & Kluska, along with Dr. Robert Fine from New York-Presbyterian/Columbia University Medical Center review current treatment paradigm for advanced and metastatic colorectal cancer (CRC) and discuss new treatments for CRC on an Analyst/Industry conference call to be held on April 6 at 11 am.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Friday
Options
Opening call sale in Pfizer struck 7.4% above spot » 13:30
04/03/20
04/03
13:30
04/03/20
13:30
PFE

Pfizer

$33.42 /

+0.57 (+1.74%)

Opening call sale in…

Opening call sale in Pfizer struck 7.4% above spot. Shares up 2% today near $33.50 with a large trade on the ISE where a customer sold 10K June 36 calls for 91c to open a new position. Trade details show the sale was made in the form of an electronic auction, with a single buyer paying 2c above the 89c best bid for the order.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
Cantor pharma/biotech analysts to hold analyst/industry conference call » 10:21
04/03/20
04/03
10:21
04/03/20
10:21
PFE

Pfizer

$33.66 /

+0.81 (+2.47%)

, LLY

Eli Lilly

$142.95 /

+0.8 (+0.56%)

, MRK

Merck

$77.00 /

+0.09 (+0.12%)

, MRTX

Mirati Therapeutics

$76.21 /

+0.84 (+1.11%)

, AMGN

Amgen

$207.69 /

-1.35 (-0.65%)

, JNJ

Johnson & Johnson

$133.95 /

+0.87 (+0.65%)

, PHGE

BiomX

$7.00 /

+ (+0.00%)

Cantor Fitzgerald…

Cantor Fitzgerald Pharmaceuticals Analyst Chen & Kim, Biotech Analysts Young, Kumar & Kluska, along with Dr. Robert Fine from New York-Presbyterian/Columbia University Medical Center review current treatment paradigm for advanced and metastatic colorectal cancer (CRC) and discuss new treatments for CRC on an Analyst/Industry conference call to be held on April 6 at 11 am.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Icon signs new service agreement with Pfizer » 09:14
04/03/20
04/03
09:14
04/03/20
09:14
ICLR

Icon

$129.69 /

-2.86 (-2.16%)

, PFE

Pfizer

$32.85 /

+1.12 (+3.53%)

ICON (ICLR) announced it…

ICON (ICLR) announced it has signed a three-year agreement with Pfizer (PFE). Under the terms of the agreement, Pfizer has the right to extend the term for up to an additional two years. Financial details of the agreement were not disclosed. The agreement builds on the companies' existing relationship, under which ICON provides global expertise in the planning, execution, management and conduct of clinical trials.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
BioNTech price target raised to $60 from $22 at Canaccord » 08:54
04/03/20
04/03
08:54
04/03/20
08:54
BNTX

BioNTech

$56.05 /

+3.07 (+5.79%)

, PFE

Pfizer

$32.85 /

+1.12 (+3.53%)

Canaccord analyst Arlinda…

Canaccord analyst Arlinda Lee raised the firm's price target on BioNTech (BNTX) to $60 from $22 and keeps a Buy rating on the shares.The analyst noted its COVID-19 vaccine candidate which is partnered with Pfizer (PFE) will enter the clinic in April as the company continues to advance its pipeline.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Thursday
Hot Stocks
Pfizer announces European approval of MabThera biosimilar » 14:07
04/02/20
04/02
14:07
04/02/20
14:07
PFE

Pfizer

$32.47 /

+0.74 (+2.33%)

Pfizer announced that the…

Pfizer announced that the European Commission has approved Ruxience, a monoclonal antibody and biosimilar to MabThera, for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis , granulomatosis with polyangiitis and microscopic polyangiitis, and pemphigus vulgaris.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Wednesday
Hot Stocks
Merck, Pfizer, Lilly announces medical volunteer service programs » 16:01
04/01/20
04/01
16:01
04/01/20
16:01
MRK

Merck

$73.38 /

-3.615 (-4.70%)

, PFE

Pfizer

$31.72 /

-1.005 (-3.07%)

, LLY

Eli Lilly

$135.71 /

-2.67 (-1.93%)

Merck (MRK), Pfizer…

Merck (MRK), Pfizer (PFE), and Eli Lilly (LLY) announced medical service volunteer programs to enable employees who are licensed medical professionals to aid in the fight against COVID-19 while maintaining their base pay. Together, these three major biopharmaceutical companies employ thousands of doctors, nurses, pharmacists, medical laboratory technicians and other medical professionals whose services are in high demand during the COVID-19 pandemic. Some of these companies are expanding their existing corporate volunteer programs so that qualified employees who opt to serve can do so for a longer period of time than normally allowed. Merck will support its employees around the world who are uniquely qualified to provide medical services and wish to aid communities affected by the COVID-19 pandemic. In the U.S., Merck intends to collaborate with The Health Management Academy to identify facilities with the greatest need and triage potential qualifying volunteers to serve. Pfizer has created a new Global COVID-19 Medical Service Program that empowers medical colleagues to provide diagnostic, treatment, and public health support in the battle against COVID-19. Licensed medical professionals who feel duty-bound to provide their services during this crisis will now have a way to engage in the fight against COVID-19. Colleagues will continue to receive their full pay, benefits, and be able to return to their position upon completion of service. Lilly is deploying its medical professionals to staff a free drive-through COVID-19 testing facility at its corporate headquarters in Indianapolis. The testing facility serves active frontline health care workers and first responders, as a service to the community and in an effort to protect people working on the front lines of this pandemic. Lilly scientists are using the company's specialized research laboratories to analyze the tests, as well as samples taken in Indiana health care facilities, including nursing homes and emergency rooms, in partnership with the Indiana State Department of Health. Lilly is also allowing trained medical professionals to volunteer in service of patients.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Over a week ago
Hot Stocks
Mylan, Pfizer say combination between Mylan, Upjohn to close in 2H20 » 06:48
03/26/20
03/26
06:48
03/26/20
06:48
MYL

Mylan

$15.01 /

-0.14 (-0.92%)

, PFE

Pfizer

$29.77 /

+0.07 (+0.24%)

Mylan (MYL) and Pfizer…

Mylan (MYL) and Pfizer (PFE) announced that due to the unprecedented circumstances surrounding the COVID-19 pandemic, including associated delays in the regulatory review process, the proposed transaction involving Mylan and Upjohn, a division of Pfizer, is now anticipated to close in the second half of 2020. There are no additional changes to the previously announced terms or plans regarding the transaction. The two companies remain highly confident in the benefits of the pending transaction to their respective shareholders and other stakeholders. Mylan, Pfizer and Upjohn are working closely on integration planning and are making significant progress toward Day 1 readiness. Together the companies continue to progress toward a successful close. The primary focus of both companies remains the health and safety of their dedicated and valued employees who are working tirelessly towards completion of this transaction while also maintaining their responsibility to meet patient needs during this extraordinary time. Also, in light of increased meeting and other restrictions due to COVID-19 developments in the Netherlands, where Mylan is incorporated, Mylan's extraordinary general meeting of shareholders to approve certain matters in connection with the transaction has been rescheduled from April 27, to June 30, and will be hosted in conjunction with the company's annual general meeting of shareholders which is being scheduled for the same day. Accordingly, the record date for the EGM and the AGM in respect of Mylan's ordinary shares is June 2, 2020 and the cut-off time for the EGM and the AGM - which is the time prior to which holders of Mylan ordinary shares can give notice of attendance at the applicable meeting or vote by internet or telephone or by submitting a proxy card. Mylan and Pfizer continue to look forward to the proposed combination creating a new champion for global health at the close of this transaction.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.